AroCell AB

Equities

AROC

SE0003883990

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:12:45 2024-05-31 EDT			5-day change	1st Jan Change
0.441 ^SEK	+2.56%		+9.70%	+0.92%

05-03	AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Swedish Diagnostics Company AroCell Secures US Patent	MT

AroCell AB Appoints Jon Eiken as Chairman of the Nomination Committee

February 13, 2018 at 01:32 pm

AroCell AB (publ) announced that Jon Eiken has been appointed Chairman of the Nomination Committee. The nomination committee includes Bernhard Tribukait, Staffan Eriksson, Jon Eiken and Claes Post board chairman.

Latest news about AroCell AB

AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Swedish Diagnostics Company AroCell Secures US Patent	04-18	MT
AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
AroCell AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
AroCell Names CFO Goes on Parental Leave, Interim CFO Named	02-01	MT
AroCell AB Announces Chief Financial Officer Changes	02-01	CI
AroCell Wins Regulatory Nod for Typhoid Fever Rapid Test in Ethiopia	01-25	MT
AroCell AB Obtains Regulatory Approval for TUBEX® TF in Ethiopia	01-25	CI
AroCell AB Announces Results of Serum Tk1 Protein Levels Can Predict the Survival of Patients with Metastatic Prostate Cancer Patients	01-15	CI
AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
AroCell AB Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer	23-09-18	CI
AroCell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
AroCell AB Signs Additional Agreement with ZECEN Biotech Co., Ltd	23-07-17	CI
AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
AroCell AB Announces TK1 together with PSA can predict more than 10 years differences in survival in men with prostate cancer	23-03-09	CI
Arocell AB Announces Improved Early Detection of Ovarian Cancer with Dual Biomarker Algorithm	23-03-06	CI
AroCell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
AroCell Signs Distribution Agreement in Ethiopia	23-02-01	CI
AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-27	CI
AroCell Signs Distribution Agreement with MM African Technology Covering Zambia and Malawi	22-10-19	CI
AroCell To Register TPS CLIA Tumor Marker In Chinese Market	22-09-06	MT
AroCell AB Expands Its Presence in the Chinese Market	22-09-06	CI
AroCell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-17	CI
AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument	22-06-13	CI
AroCell AB Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market	22-05-12	CI

Chart AroCell AB

Duration

Period

More charts

Company Profile

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for AroCell AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROCELL AB	+0.92%	9.35M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B

Other Biotechnology & Medical Research